3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
54
Multiple Myeloma
45
Lymphoma
44
Lymphoma, Non-Hodgkin
41
Leukemia
38
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Hodgkin Disease
35
Myelodysplastic Syndromes
34
Lymphoma, Mantle-Cell
20
Lymphoma, Large B-Cell, Diffuse
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
19
Leukemia, Lymphocytic, Chronic, B-Cell
16
Burkitt Lymphoma
16
Breast Neoplasms
13
Neoplasms, Plasma Cell
11
Recurrence
10
Lymphoma, Follicular
10
Hematologic Neoplasms
9
Anemia, Refractory, with Excess of Blasts
9
Lymphoma, B-Cell, Marginal Zone
8
Neuroblastoma
7
Myeloproliferative Disorders
7
Lymphoma, Large-Cell, Immunoblastic
7
Central Nervous System Neoplasms
7
Blast Crisis
7
Neoplasms
6
Lymphoma, T-Cell
6
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myelomonocytic, Chronic
6
Graft vs Host Disease
6
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled